Cargando…

Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis

Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five effective rounds of mass drug administration (MDA) and demonstrating low prevalence in subsequent assessments. The first assessments recommended by the World Health Organization (WHO) are sentine...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgert-Brucker, Clara R., Zoerhoff, Kathryn L., Headland, Maureen, Shoemaker, Erica A., Stelmach, Rachel, Karim, Mohammad Jahirul, Batcho, Wilfrid, Bougouma, Clarisse, Bougma, Roland, Benjamin Didier, Biholong, Georges, Nko'Ayissi, Marfo, Benjamin, Lemoine, Jean Frantz, Pangaribuan, Helena Ullyartha, Wijayanti, Eksi, Coulibaly, Yaya Ibrahim, Doumbia, Salif Seriba, Rimal, Pradip, Salissou, Adamou Bacthiri, Bah, Yukaba, Mwingira, Upendo, Nshala, Andreas, Muheki, Edridah, Shott, Joseph, Yevstigneyeva, Violetta, Ndayishimye, Egide, Baker, Margaret, Kraemer, John, Brady, Molly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289444/
https://www.ncbi.nlm.nih.gov/pubmed/32479495
http://dx.doi.org/10.1371/journal.pntd.0008301
_version_ 1783545465754615808
author Burgert-Brucker, Clara R.
Zoerhoff, Kathryn L.
Headland, Maureen
Shoemaker, Erica A.
Stelmach, Rachel
Karim, Mohammad Jahirul
Batcho, Wilfrid
Bougouma, Clarisse
Bougma, Roland
Benjamin Didier, Biholong
Georges, Nko'Ayissi
Marfo, Benjamin
Lemoine, Jean Frantz
Pangaribuan, Helena Ullyartha
Wijayanti, Eksi
Coulibaly, Yaya Ibrahim
Doumbia, Salif Seriba
Rimal, Pradip
Salissou, Adamou Bacthiri
Bah, Yukaba
Mwingira, Upendo
Nshala, Andreas
Muheki, Edridah
Shott, Joseph
Yevstigneyeva, Violetta
Ndayishimye, Egide
Baker, Margaret
Kraemer, John
Brady, Molly
author_facet Burgert-Brucker, Clara R.
Zoerhoff, Kathryn L.
Headland, Maureen
Shoemaker, Erica A.
Stelmach, Rachel
Karim, Mohammad Jahirul
Batcho, Wilfrid
Bougouma, Clarisse
Bougma, Roland
Benjamin Didier, Biholong
Georges, Nko'Ayissi
Marfo, Benjamin
Lemoine, Jean Frantz
Pangaribuan, Helena Ullyartha
Wijayanti, Eksi
Coulibaly, Yaya Ibrahim
Doumbia, Salif Seriba
Rimal, Pradip
Salissou, Adamou Bacthiri
Bah, Yukaba
Mwingira, Upendo
Nshala, Andreas
Muheki, Edridah
Shott, Joseph
Yevstigneyeva, Violetta
Ndayishimye, Egide
Baker, Margaret
Kraemer, John
Brady, Molly
author_sort Burgert-Brucker, Clara R.
collection PubMed
description Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five effective rounds of mass drug administration (MDA) and demonstrating low prevalence in subsequent assessments. The first assessments recommended by the World Health Organization (WHO) are sentinel and spot-check sites—referred to as pre-transmission assessment surveys (pre-TAS)—in each implementation unit after MDA. If pre-TAS shows that prevalence in each site has been lowered to less than 1% microfilaremia or less than 2% antigenemia, the implementation unit conducts a TAS to determine whether MDA can be stopped. Failure to pass pre-TAS means that further rounds of MDA are required. This study aims to understand factors influencing pre-TAS results using existing programmatic data from 554 implementation units, of which 74 (13%) failed, in 13 countries. Secondary data analysis was completed using existing data from Bangladesh, Benin, Burkina Faso, Cameroon, Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and Uganda. Additional covariate data were obtained from spatial raster data sets. Bivariate analysis and multilinear regression were performed to establish potential relationships between variables and the pre-TAS result. Higher baseline prevalence and lower elevation were significant in the regression model. Variables statistically significantly associated with failure (p-value ≤0.05) in the bivariate analyses included baseline prevalence at or above 5% or 10%, use of Filariasis Test Strips (FTS), primary vector of Culex, treatment with diethylcarbamazine-albendazole, higher elevation, higher population density, higher enhanced vegetation index (EVI), higher annual rainfall, and 6 or more rounds of MDA. This paper reports for the first time factors associated with pre-TAS results from a multi-country analysis. This information can help countries more effectively forecast program activities, such as the potential need for more rounds of MDA, and prioritize resources to ensure adequate coverage of all persons in areas at highest risk of failing pre-TAS.
format Online
Article
Text
id pubmed-7289444
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-72894442020-06-18 Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis Burgert-Brucker, Clara R. Zoerhoff, Kathryn L. Headland, Maureen Shoemaker, Erica A. Stelmach, Rachel Karim, Mohammad Jahirul Batcho, Wilfrid Bougouma, Clarisse Bougma, Roland Benjamin Didier, Biholong Georges, Nko'Ayissi Marfo, Benjamin Lemoine, Jean Frantz Pangaribuan, Helena Ullyartha Wijayanti, Eksi Coulibaly, Yaya Ibrahim Doumbia, Salif Seriba Rimal, Pradip Salissou, Adamou Bacthiri Bah, Yukaba Mwingira, Upendo Nshala, Andreas Muheki, Edridah Shott, Joseph Yevstigneyeva, Violetta Ndayishimye, Egide Baker, Margaret Kraemer, John Brady, Molly PLoS Negl Trop Dis Research Article Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five effective rounds of mass drug administration (MDA) and demonstrating low prevalence in subsequent assessments. The first assessments recommended by the World Health Organization (WHO) are sentinel and spot-check sites—referred to as pre-transmission assessment surveys (pre-TAS)—in each implementation unit after MDA. If pre-TAS shows that prevalence in each site has been lowered to less than 1% microfilaremia or less than 2% antigenemia, the implementation unit conducts a TAS to determine whether MDA can be stopped. Failure to pass pre-TAS means that further rounds of MDA are required. This study aims to understand factors influencing pre-TAS results using existing programmatic data from 554 implementation units, of which 74 (13%) failed, in 13 countries. Secondary data analysis was completed using existing data from Bangladesh, Benin, Burkina Faso, Cameroon, Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and Uganda. Additional covariate data were obtained from spatial raster data sets. Bivariate analysis and multilinear regression were performed to establish potential relationships between variables and the pre-TAS result. Higher baseline prevalence and lower elevation were significant in the regression model. Variables statistically significantly associated with failure (p-value ≤0.05) in the bivariate analyses included baseline prevalence at or above 5% or 10%, use of Filariasis Test Strips (FTS), primary vector of Culex, treatment with diethylcarbamazine-albendazole, higher elevation, higher population density, higher enhanced vegetation index (EVI), higher annual rainfall, and 6 or more rounds of MDA. This paper reports for the first time factors associated with pre-TAS results from a multi-country analysis. This information can help countries more effectively forecast program activities, such as the potential need for more rounds of MDA, and prioritize resources to ensure adequate coverage of all persons in areas at highest risk of failing pre-TAS. Public Library of Science 2020-06-01 /pmc/articles/PMC7289444/ /pubmed/32479495 http://dx.doi.org/10.1371/journal.pntd.0008301 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Burgert-Brucker, Clara R.
Zoerhoff, Kathryn L.
Headland, Maureen
Shoemaker, Erica A.
Stelmach, Rachel
Karim, Mohammad Jahirul
Batcho, Wilfrid
Bougouma, Clarisse
Bougma, Roland
Benjamin Didier, Biholong
Georges, Nko'Ayissi
Marfo, Benjamin
Lemoine, Jean Frantz
Pangaribuan, Helena Ullyartha
Wijayanti, Eksi
Coulibaly, Yaya Ibrahim
Doumbia, Salif Seriba
Rimal, Pradip
Salissou, Adamou Bacthiri
Bah, Yukaba
Mwingira, Upendo
Nshala, Andreas
Muheki, Edridah
Shott, Joseph
Yevstigneyeva, Violetta
Ndayishimye, Egide
Baker, Margaret
Kraemer, John
Brady, Molly
Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis
title Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis
title_full Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis
title_fullStr Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis
title_full_unstemmed Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis
title_short Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis
title_sort risk factors associated with failing pre-transmission assessment surveys (pre-tas) in lymphatic filariasis elimination programs: results of a multi-country analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289444/
https://www.ncbi.nlm.nih.gov/pubmed/32479495
http://dx.doi.org/10.1371/journal.pntd.0008301
work_keys_str_mv AT burgertbruckerclarar riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT zoerhoffkathrynl riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT headlandmaureen riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT shoemakerericaa riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT stelmachrachel riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT karimmohammadjahirul riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT batchowilfrid riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT bougoumaclarisse riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT bougmaroland riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT benjamindidierbiholong riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT georgesnkoayissi riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT marfobenjamin riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT lemoinejeanfrantz riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT pangaribuanhelenaullyartha riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT wijayantieksi riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT coulibalyyayaibrahim riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT doumbiasalifseriba riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT rimalpradip riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT salissouadamoubacthiri riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT bahyukaba riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT mwingiraupendo riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT nshalaandreas riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT muhekiedridah riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT shottjoseph riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT yevstigneyevavioletta riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT ndayishimyeegide riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT bakermargaret riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT kraemerjohn riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis
AT bradymolly riskfactorsassociatedwithfailingpretransmissionassessmentsurveyspretasinlymphaticfilariasiseliminationprogramsresultsofamulticountryanalysis